MA56190A - Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde - Google Patents

Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde

Info

Publication number
MA56190A
MA56190A MA056190A MA56190A MA56190A MA 56190 A MA56190 A MA 56190A MA 056190 A MA056190 A MA 056190A MA 56190 A MA56190 A MA 56190A MA 56190 A MA56190 A MA 56190A
Authority
MA
Morocco
Prior art keywords
tocilizumab
dosage
rheumatoid arthritis
subcutaneous
modified
Prior art date
Application number
MA056190A
Other languages
English (en)
Inventor
Chieh-I Chen
Wenhui Wei
Original Assignee
Chen Chieh I
Regeneron Pharma
Sanofi Biotechnology
Wenhui Wei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chen Chieh I, Regeneron Pharma, Sanofi Biotechnology, Wenhui Wei filed Critical Chen Chieh I
Publication of MA56190A publication Critical patent/MA56190A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA056190A 2019-06-12 2020-06-11 Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde MA56190A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860611P 2019-06-12 2019-06-12
EP20305192 2020-02-27

Publications (1)

Publication Number Publication Date
MA56190A true MA56190A (fr) 2022-04-20

Family

ID=71170831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056190A MA56190A (fr) 2019-06-12 2020-06-11 Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde

Country Status (13)

Country Link
US (1) US20220242959A1 (fr)
EP (1) EP3983071A1 (fr)
JP (2) JP2022536739A (fr)
KR (1) KR20230047944A (fr)
CN (1) CN115003382A (fr)
AU (1) AU2020290484A1 (fr)
BR (1) BR112021025060A2 (fr)
CA (1) CA3143261A1 (fr)
CO (1) CO2022000064A2 (fr)
IL (1) IL288690A (fr)
MA (1) MA56190A (fr)
MX (1) MX2021015336A (fr)
WO (1) WO2020252214A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202106712A (zh) 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
CN115825415B (zh) * 2022-09-28 2023-07-14 珠海重链生物科技有限公司 阻断剂和体外免疫诊断产品、应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR102116202B1 (ko) * 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체

Also Published As

Publication number Publication date
CA3143261A1 (fr) 2020-12-17
CN115003382A (zh) 2022-09-02
IL288690A (en) 2022-02-01
KR20230047944A (ko) 2023-04-10
CO2022000064A2 (es) 2022-04-08
US20220242959A1 (en) 2022-08-04
WO2020252214A1 (fr) 2020-12-17
JP2022536739A (ja) 2022-08-18
EP3983071A1 (fr) 2022-04-20
JP2026032195A (ja) 2026-02-25
AU2020290484A1 (en) 2021-12-23
BR112021025060A2 (pt) 2022-02-22
MX2021015336A (es) 2022-10-21

Similar Documents

Publication Publication Date Title
EP3930753A4 (fr) Banques de variants d'acides nucléiques pour le récepteur glp1
EP3765123A4 (fr) Capuchons désinfectants pour raccords médicaux
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
EP3432781A4 (fr) Processeur de report implantable pour un implant d'alerte
EP3762414A4 (fr) Dosages pour détecter la neurodégénérescence
EP4062010A4 (fr) Vibrateur de béton
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
DK3793960T3 (da) Kalkmælk
EP3810177A4 (fr) Peptides cycliques pour l'inhibition de la pcsk9
IL287904A (en) Combination treatment of arthritic disease
MA53551A (fr) Dosage nocturne chronique de lasmiditan pour la prévention de la migraine
MA41314A (fr) Régime posologique pour antagonistes de madcam
MA56190A (fr) Dosage modifié de tocilizumab sous-cutané pour la polyarthrite rhumatoïde
EP3992176A4 (fr) Antagoniste d'ep2
EP3612214A4 (fr) Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP4069604C0 (fr) Conteneur inviolable
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP4071066A4 (fr) Récipient de canette
EP3472320A4 (fr) Dysferline tronquée pour le traitement de la dysferlinopathie
EP3853250A4 (fr) Ptprs et protéoglycanes pour la polyarthrite rhumatoïde
ES1230591Y (es) Contenedor sanitario
EP3981991A4 (fr) Structure de fixation pour tuyauterie
EP3866770C0 (fr) Nouvelle forme posologique
EP3813812A4 (fr) Dosage d'acétaminophène
EP3787884A4 (fr) Système de pré-compression pour pré-compression d'une structure